Chronic kidney disease and its complications.

Chronic kidney disease (CKD) is a complex disease affecting more than 20 million individuals in the United States. Progression of CKD is associated with a number of serious complications, including increased incidence of cardiovascular disease, hyperlipidemia, anemia, and metabolic bone disease. CKD patients should be assessed for the presence of these complications and receive optimal treatment to reduce their morbidity and mortality. A multidisciplinary approach is required to accomplish this goal.

[1]  R M Hakim,et al.  Initiation of dialysis. , 1994, Advances in nephrology from the Necker Hospital.

[2]  A. Folsom,et al.  Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. , 2005, Journal of the American Society of Nephrology : JASN.

[3]  C. Blum,et al.  The hyperlipidemia of the nephrotic syndrome. , 1985, The American journal of medicine.

[4]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[5]  J. Coresh,et al.  Prevalence of chronic kidney disease in the United States. , 2007, JAMA.

[6]  R. Cooper,et al.  Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. , 2005, Journal of the American Society of Nephrology : JASN.

[7]  B. Kestenbaum,et al.  Serum phosphate levels and mortality risk among people with chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[8]  S. Aronoff,et al.  The prevalence of anemia in patients with chronic kidney disease , 2004, Current medical research and opinion.

[9]  R. Foley,et al.  Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  K. Calman,et al.  INCREASED VASCULAR PERMEABILITY: A MAJOR CAUSE OF HYPOALBUMINAEMIA IN DISEASE AND INJURY , 1985, The Lancet.

[11]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  R. Wolfe,et al.  Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[14]  Abdullah M W El-Kishawi,et al.  Renal osteodystrophy: review of the disease and its treatment. , 2006, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[15]  B. Kasiske.  Hyperlipidemia in patients with chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  Winfried März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005 .

[17]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[18]  Harlan M Krumholz,et al.  Renal impairment and outcomes in heart failure: systematic review and meta-analysis. , 2006, Journal of the American College of Cardiology.

[19]  D. Abrahamson,et al.  Derivation and differentiation of glomerular endothelial cells. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  Feng Lin,et al.  The Incidence of End-Stage Renal Disease Is Increasing Faster than the Prevalence of Chronic Renal Insufficiency , 2004, Annals of Internal Medicine.

[21]  J. Coresh,et al.  Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. , 2000, Kidney international.

[22]  Sempos Ct,et al.  Summary of the Second Report of the National Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993 .

[23]  M. Pfeffer,et al.  Effect of pravastatin in people with diabetes and chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[24]  F. Dekker,et al.  The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  F. Llach,et al.  Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  汪关煜.  Renal osteodystrophy , 2002 .

[27]  S. Moe.  Vascular calcification and renal osteodystrophy relationship in chronic kidney disease , 2006, European journal of clinical investigation.

[28]  K. Iseki,et al.  Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. , 2002, Kidney international.

[29]  G. Eknoyan,et al.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2005, Kidney international.

[30]  A. Levin,et al.  Defining a renal anemia management period. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  T. Dowling.  Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[32]  Hutch Ja.  Vascular calcification in dialysis patients. , 2007 .

[33]  E G Lowrie,et al.  The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. , 1993, The New England journal of medicine.

[34]  S. Draibe,et al.  The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  A R Nissenson,et al.  The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. , 1998, The New England journal of medicine.

[36]  A. Levin,et al.  Vascular calcification in chronic kidney disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  T. Ikizler,et al.  Therapeutic effects of oral nutritional supplementation during hemodialysis. , 2002, Kidney international.

[38]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  T. Tanaka,et al.  Oncotic pressure regulates gene transcriptions of albumin and apolipoprotein B in cultured rat hepatoma cells. , 1992, The American journal of physiology.

[40]  N. Mittman,et al.  Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  C Safran,et al.  Serum albumin level on admission as a predictor of death, length of stay, and readmission. , 1992, Archives of internal medicine.

[42]  J. Fink,et al.  Use of erythropoietin before the initiation of dialysis and its impact on mortality. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  I. Khan,et al.  Death during the first 90 days of dialysis: a case control study. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[44]  S. Sprague,et al.  Bone health in chronic kidney disease-mineral and bone disease. , 2007, Advances in chronic kidney disease.

[45]  S. Cummings,et al.  Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. , 2006, Archives of internal medicine.

[46]  P. Ratcliffe.  Molecular biology of erythropoietin. , 1993, Kidney international.

[47]  M. Sarnak,et al.  The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  F Dumler,et al.  Use of bioelectric impedance analysis and dual-energy X-ray absorptiometry for monitoring the nutritional status of dialysis patients. , 1997, ASAIO journal.

[49]  Christine M. Hoehner,et al.  Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. , 2002, Journal of the American Society of Nephrology : JASN.

[50]  M. Pfisterer,et al.  Anemia as independent predictor of major events in elderly patients with chronic angina. , 2006, American heart journal.

[51]  C. Combe,et al.  Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): nutrition guidelines, indicators, and practices. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[52]  P. Ballmer,et al.  Acute suppression of albumin synthesis in systemic inflammatory disease: an individually graded response of rat hepatocytes. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[53]  G. Eknoyan,et al.  Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.

[54]  J. Singer,et al.  Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[55]  M. Joy,et al.  Outcomes of Secondary Hyperparathyroidism in Chronic Kidney Disease and the Direct Costs of Treatment , 2007, Journal of managed care pharmacy : JMCP.

[56]  M. Nieminen,et al.  Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study , 2002, Journal of hypertension.

[57]  Kdoqi Disclaimer,et al.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[58]  A. Griffiths,et al.  Analysis of the effects of increasing delivered dialysis treatment to malnourished peritoneal dialysis patients. , 2000, Kidney international.

[59]  Grace H. Lee,et al.  Impact of kidney bone disease and its management on survival of patients on dialysis. , 2007, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.